Skip to content

Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise


The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger. Read More]

Leave a Reply

Your email address will not be published. Required fields are marked *